Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Assessmet of Patients With PAH Right Ventricular Volume


Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension




The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with Pulmonary Arterial Hypertension (PAH). The trial will be defined as positive if the mean VMS-cMRI percent difference is <10% and >-10% at a 1-sided 0.025 statistical significance level for RVEDV and for RVESV, with no safety concerns for the VMS procedure.

Study Status: Active, not recruiting


Condition Intervention Phase
Pulmonary Arterial Hypertension Device: Ventripoint Medical System Phase 3

Verified by VentriPoint Diagnostics Ltd. October, 2012

Sponsored by: VentriPoint Diagnostics Ltd.
Information provided by: VentriPoint Diagnostics Ltd. identifier: NCT01557582

Study Type: Interventional

Study Design: Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label

Cleveland Clinic
Cleveland, Ohio 44195
United States

Robyn Barst, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site